Compare Funko Inc (FNKO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Tango Therapeutics Inc. — how do they compare? Funko Inc trades at $6.31 (market cap $355.57M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 10.5× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Tango Therapeutics Inc. for 0 Days on average.
| FNKO | TNGX | |
|---|---|---|
Market Cap | $355.57M | $3.74B |
Volume | 738,460 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $32.90 |
52-Week Low | $2.81 | $7.50 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $576.22M | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.52, up 0.93% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% to $207.7M, and raised EBITDA guidance to $105M. Despite negative net margins, the stock trades at attractive valuations with P/S of 0.39x and EV/EBITDA of 6.84x. Recent management changes and product expansions signal strategic momentum.
FNKO presents a turnaround opportunity with improving operational metrics and positive analyst sentiment, though risks remain from inconsistent profitability and high debt levels. The consensus price target of $7.58 suggests 16% upside potential, supported by strong Q2 results and raised guidance. Investors should weigh the company's progress against ongoing margin pressures and competitive challenges in the collectibles market.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
